INBX
Inhibrx Biosciences, Inc.
95.10$
+2.5%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Cash Flow
Inhibrx Biosciences, Inc. (INBX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Operating Cash Flow" came in at -30 million USD. Tick rows to compare them in a chart.
All figures in millions of USD.
Tick rows to compare them in a chart (up to 4)
| Line item | Q4 17 | Q1 18 | Q2 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -7.0 | -2.1 | -13 | -6.9 | -5.6 | -14 | -0.8 | -12 | -7.4 | -11 | -14 | -15 | -22 | -22 | -14 | -23 | -27 | -27 | -31 | -31 | -27 | -42 | -54 | -57 | -63 | -57 | -30 | -44 | -36 | -30 | -34 | -30 | -38 | -30 | -132 | |
| 0.1 | 0.2 | 0.2 | 0.2 | 0.8 | -0.4 | 0.5 | 0.2 | 0.3 | 0.2 | 0.2 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.3 | 0.4 | 0.5 | 0.8 | 0.7 | 0.7 | 0.7 | 0.6 | 0.6 | 0.5 | 0.5 | 2.2 | |
| 0.4 | 0.3 | 1.8 | 0.3 | 0.9 | 0.9 | 1.0 | 1.1 | 1.1 | 1.3 | 1.3 | 1.4 | 3.4 | 4.0 | 3.5 | 4.2 | 5.1 | 5.3 | 4.7 | 5.4 | 4.7 | 6.3 | 6.5 | 2.3 | 6.4 | 48 | 3.0 | 3.0 | 2.5 | 2.8 | 3.2 | 2.7 | 2.7 | 3.1 | 12 | |
| 1.0 | 6.6 | -8.1 | -1.3 | -3.5 | -4.5 | 11 | 0.1 | 9.4 | 3.1 | 0.0 | 0.1 | -6.6 | -6.5 | 2.3 | -2.6 | -2.0 | 4.1 | -2.0 | 3.0 | 7.3 | -3.4 | -11 | 28 | 7.2 | 35 | 9.4 | 0.0 | 3.3 | -5.8 | -3.4 | -1.7 | -9.0 | 1.3 | -13 | |
| 0.2 | 0.1 | 0.5 | 0.6 | 0.1 | 0.7 | 0.7 | 0.3 | 0.1 | 0.4 | 0.3 | 0.6 | 0.0 | 0.4 | 0.2 | 0.3 | 0.1 | 0.3 | 0.0 | 0.3 | 0.0 | 0.3 | 0.8 | 3.4 | 1.1 | 1.2 | 0.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| -0.2 | -0.1 | -0.5 | -0.6 | -0.1 | -0.7 | -0.7 | -0.3 | -0.1 | -0.4 | -0.3 | -0.6 | 0.0 | -0.4 | -0.2 | -0.3 | -0.1 | -0.3 | 0.0 | -0.3 | 0.0 | -0.3 | -0.8 | -3.4 | -1.1 | -1.2 | -0.2 | 0.0 | 0.0 | – | 0.0 | – | – | 0.0 | – | |
| 0.1 | 0.4 | 0.5 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | 0.0 | – | 100 | 0.0 | 0.0 | 0.0 | 75 | 0.0 | 75 | |
| -1.5 | -1.8 | 7.1 | 6.7 | 9.8 | 36 | -1.9 | -0.4 | -3.6 | 17 | 136 | 17 | 1.0 | 40 | 0.8 | 41 | 39 | 60 | 0.5 | 159 | 27 | 0.9 | 200 | 0.9 | 39 | 33 | 2.7 | 0.0 | 100 | 0.0 | 0.4 | 1.3 | 75 | 1.6 | 79 | |
| 13 | -3.9 | -6.4 | 2.1 | 4.1 | 21 | -3.4 | -13 | -11 | 5.2 | 122 | 1.0 | -21 | 18 | -13 | 19 | 12 | 33 | -30 | 128 | -40 | -42 | 145 | 278 | -25 | -26 | -31 | -44 | 64 | -30 | -33 | -29 | 37 | -28 | -53 | |
| -7.2 | -2.2 | -14 | -7.5 | -5.7 | -14 | -1.5 | -12 | -7.5 | -12 | -14 | -16 | -22 | -23 | -14 | -23 | -27 | -27 | -31 | -31 | -27 | -43 | -55 | -60 | -64 | -59 | -31 | -44 | -36 | -30 | -34 | -30 | -38 | -30 | -132 |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.